OBJECTIVE: To estimate the cost-effectiveness of HIV screening strategies for the prevention of perinatal transmission in Uganda, a resource-limited country with high HIV prevalence and incidence. STUDY DESIGN: We designed a decision analytic model from a health care system perspective to assess the vertical transmission rates and cost-effectiveness of 4 different HIV screening strategies in pregnancy: (1) rapid HIV antibody (Ab) test at initial visit (current standard of care), (2) strategy 1 + HIV RNA at initial visit (adds detection of acute HIV), (3) strategy 1 + repeat HIV Ab at delivery (adds detection of incident HIV), and (4) strategy 3 + HIV RNA at delivery (adds detection of acute HIV at delivery). Model estimates were derived from the literature and local sources, and life years saved were discounted at a rate of 3% per year. Based on World Health Organization guidelines, we defined our cost-effectiveness threshold as ≤3 times the gross domestic product per capita, which for Uganda was US$3300 in 2008. RESULTS: Using base case estimates of 10% HIV prevalence among women entering prenatal care and 3% incidence during pregnancy, strategy 3 was incrementally the cost-effective option that led to the greatest total life years. CONCLUSIONS: Repeat rapid HIV Ab testing at the time of labor is a cost-effective strategy even in a resource-limited setting such as Uganda.
OBJECTIVE: To estimate the cost-effectiveness of HIV screening strategies for the prevention of perinatal transmission in Uganda, a resource-limited country with high HIV prevalence and incidence. STUDY DESIGN: We designed a decision analytic model from a health care system perspective to assess the vertical transmission rates and cost-effectiveness of 4 different HIV screening strategies in pregnancy: (1) rapid HIV antibody (Ab) test at initial visit (current standard of care), (2) strategy 1 + HIV RNA at initial visit (adds detection of acute HIV), (3) strategy 1 + repeat HIV Ab at delivery (adds detection of incident HIV), and (4) strategy 3 + HIV RNA at delivery (adds detection of acute HIV at delivery). Model estimates were derived from the literature and local sources, and life years saved were discounted at a rate of 3% per year. Based on World Health Organization guidelines, we defined our cost-effectiveness threshold as ≤3 times the gross domestic product per capita, which for Uganda was US$3300 in 2008. RESULTS: Using base case estimates of 10% HIV prevalence among women entering prenatal care and 3% incidence during pregnancy, strategy 3 was incrementally the cost-effective option that led to the greatest total life years. CONCLUSIONS: Repeat rapid HIV Ab testing at the time of labor is a cost-effective strategy even in a resource-limited setting such as Uganda.
Authors: P Nico Lelie; Harry A J van Drimmelen; H Theo M Cuypers; Susan J Best; Susan L Stramer; Catherine Hyland; Jean-Pierre Allain; Pierre Moncharmont; Christine Defer; Micha Nübling; Andreas Glauser; Marcia da Silva Cardoso; Jean-François Viret; Mervi H Lankinen; Lena Grillner; Urs Wirthmüller; Joliette Coste; Volkmar Schottstedt; Barbara Masecar; Elizabeth M Dax Journal: Transfusion Date: 2002-05 Impact factor: 3.157
Authors: K M De Cock; M G Fowler; E Mercier; I de Vincenzi; J Saba; E Hoff; D J Alnwick; M Rogers; N Shaffer Journal: JAMA Date: 2000-03-01 Impact factor: 56.272
Authors: Frederick M Hecht; Michael P Busch; Bhupat Rawal; Marcy Webb; Eric Rosenberg; Melinda Swanson; Margaret Chesney; Jennifer Anderson; Jay Levy; James O Kahn Journal: AIDS Date: 2002-05-24 Impact factor: 4.177
Authors: Peter G Cardiello; Rolf P van Heeswijk; Elly A Hassink; Preeyaporn Srasuebkul; Apicha Mahanontharit; Tarika M Samor; Wassana Worarien; Jos H Beijnen; Richard M Hoetelmans; Kiat Ruxrungtham; David A Cooper; Joep M Lange; Praphan Phanuphak Journal: J Acquir Immune Defic Syndr Date: 2002-04-15 Impact factor: 3.731
Authors: Ronald H Gray; Xianbin Li; Godfrey Kigozi; David Serwadda; Heena Brahmbhatt; Fred Wabwire-Mangen; Fred Nalugoda; Mohamed Kiddugavu; Nelson Sewankambo; Thomas C Quinn; Steven J Reynolds; Maria J Wawer Journal: Lancet Date: 2005-10-01 Impact factor: 79.321
Authors: E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson Journal: N Engl J Med Date: 1994-11-03 Impact factor: 91.245
Authors: J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro Journal: Lancet Date: 2003-09-13 Impact factor: 79.321
Authors: Christopher D Pilcher; Hsiao Chuan Tien; Joseph J Eron; Pietro L Vernazza; Szu-Yun Leu; Paul W Stewart; Li-Ean Goh; Myron S Cohen Journal: J Infect Dis Date: 2004-04-28 Impact factor: 5.226
Authors: Lisa L Abuogi; John M Humphrey; Christian Mpody; Marcel Yotebieng; Pamela M Murnane; Kate Clouse; Lindah Otieno; Craig R Cohen; Kara Wools-Kaloustian Journal: J Virus Erad Date: 2018-11-15
Authors: Benjamin H Chi; Dorothy Mbori-Ngacha; Shaffiq Essajee; Lynne M Mofenson; Fatima Tsiouris; Mary Mahy; Chewe Luo Journal: J Int AIDS Soc Date: 2020-08 Impact factor: 5.396
Authors: Julianne Meisner; D Allen Roberts; Patricia Rodriguez; Monisha Sharma; Morkor Newman Owiredu; Bertha Gomez; Maeve B de Mello; Alexey Bobrik; Arkadii Vodianyk; Andrew Storey; George Githuka; Thato Chidarikire; Ruanne Barnabas; Shiza Farid; Shaffiq Essajee; Muhammad S Jamil; Rachel Baggaley; Cheryl Johnson; Alison L Drake Journal: J Int AIDS Soc Date: 2021-04 Impact factor: 5.396